Global barbiturate drug market is anticipated to grow at a moderate CAGR of 3.5% during the forecast period (2024-2031). The rising prevalence of insomnia along with growing awareness regarding availability of drugs such as barbiturate drug for its easy treatment is a key factor driving the global barbiturate drug market. A study published in April 2020 by the American Journal of Managed Care, states that insomnia is one of the most prevalent sleep disorders and a significant financial burden on the healthcare system in the US. Over $100.0 billion is spent on insomnia-related expenses in the US each year, both direct and indirect. The use of barbiturate medications to treat common sleep problems in the elderly is becoming more and more popular globally. The demand for pharmacological remedies has increased as seniors become more conscious of the negative effects untreated sleep disturbances can have on their health.
Browse the full report description of “Barbiturate Drug Market Size, Share & Trends Analysis Report by Type (Long-acting Barbiturate, Short-acting Barbiturate, Ultra-short Acting Barbiturate and Combination Drugs), and by Application (Insomnia, Epilepsy, Sedation and Other Applications) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/barbiturate-drug-market
The ongoing trend for personalized medicine especially in the treatment of sleep disorders is further aiding to the market growth. Recent developments in genetic testing allow the identification of particular markers associated with response to barbiturate drugs or sleep disorders, allowing for more focused therapies. The ability to precisely diagnose patients enables medical practitioners to tailor treatment regimens and maximize the usage of barbiturate medications based on patient requirements.
To gain on market share, in April 2021, Ethypharm established its direct presence in Italy. It is the third largest pharmaceutical market in Europe. Under the leadership of Bruno Rago, Ethypharm Italy has reinforced the group’s commercial footprint in Europe, notably in its core therapeutic area of the Central Nervous System.
Market Coverage
• The market number available for – 2023-2031
• Base year- 2023
• Forecast period- 2024-2031
• Segment Covered-
o By Type
o By Application
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes Par Pharmaceutical, Sun Pharmaceutical Industries Ltd., Samarth Life Sciences Pvt. Ltd., Ethypharm, Abbott and Centurion Healthcare Private Ltd. among others.
Key questions addressed by the report.
Global Barbiturate Drug Market Report Segment
By Type
By Application
Global Barbiturate Drug Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/barbiturate-drug-market